Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations

How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation

(2020) Alexandros Spyridonidis   BLOOD

Molecular MRD status and outcome after transplantation in NPM1-mutated AML

(2020) Richard Dillon et al.   BLOOD

Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?

(2020) Adriano Venditti et al.   LEUKEMIA

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

(2020) Robert P. Hasserjian et al.   BLOOD

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

(2020) Ing S. Tiong et al.   BRITISH JOURNAL OF HAEMATOLOGY

Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2020) M. Heuser et al.   ANNALS OF ONCOLOGY

Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1 mutated AML patients: results from the AMLSG 09-09 Trial

(2020) Silke Kapp-Schwoerer et al.   BLOOD

NGS‐Defined Minimal Residual Disease Before Stem Cell Transplantation Predicts Acute Myeloid Leukemia Relapse

(2019) Richard D. Press et al.   AMERICAN JOURNAL OF HEMATOLOGY

Can we incorporate MRD assessment into clinical practice in AML?

(2019) Gert Ossenkoppele et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

MRD in AML: The Role of New Techniques

(2019) Maria Teresa Voso et al.   Frontiers in Oncology

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

(2019) Adriano Venditti et al.   BLOOD

Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group

(2019) Frank G. Rücker et al.   BLOOD

Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia

(2019) Federico Lussana et al.   Cancers

Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation

(2019) Megan Othus et al.   BONE MARROW TRANSPLANTATION

The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience

(2019) Justin Loke et al.   BRITISH JOURNAL OF HAEMATOLOGY

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease

(2019) Christopher S. Hourigan et al.   JOURNAL OF CLINICAL ONCOLOGY

MRD evaluation of AML in clinical practice: are we there yet?

(2019) Sylvie D. Freeman et al.   Hematology-American Society of Hematology Education Program

Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party Eu

(2018) Maria H Gilleece et al.   AMERICAN JOURNAL OF HEMATOLOGY

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia

(2018) Mithun Vinod Shah et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia

(2018) Kiyomi Morita et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

(2018) Mojca Jongen-Lavrencic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Measurable residual disease (MRD) monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

(2018) Felicitas Thol et al.   BLOOD

Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

(2018) Catherine J. Lee et al.   BONE MARROW TRANSPLANTATION

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

(2018) Uwe Platzbecker et al.   LANCET ONCOLOGY

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia

(2018) Nikhil Patkar et al.   Oncotarget

Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia

(2017) Pierre Hirsch et al.   HAEMATOLOGICA

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis

(2017) Sarah A. Buckley et al.   HAEMATOLOGICA

Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia

(2017) Pierre Hirsch et al.   HAEMATOLOGICA

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis

(2017) Sarah A. Buckley et al.   HAEMATOLOGICA

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia

(2016) Y Zhou et al.   LEUKEMIA

MRD in AML: does it already guide therapy decision-making?

(2016) G. Ossenkoppele et al.   Hematology-American Society of Hematology Education Program

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

(2015) Paresh Vyas et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation

(2015) Chiara Brambati et al.   HAEMATOLOGICA

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia

(2015) Jeffery M. Klco et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation

(2015) Chiara Brambati et al.   HAEMATOLOGICA

Donor Lymphocyte Infusion for the Treatment of Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation

(2014) Akiyoshi Takami et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Next Generation MRD

(2014) Christopher S. Hourigan   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation

(2014) R B Walter et al.   LEUKEMIA

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence

(2014) Giulio Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

(2013) R. B. Walter et al.   BLOOD

Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

(2011) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY